TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) in Non-Small Cell Lung Cancer (NSCLC)
TAFINLAR in combination with MEKINIST is indicated in adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.1,2
For the full safety profile, please refer to the Summary of Product Characteristics (SmPC) for TAFINLAR and MEKINIST.
Adverse event reporting: Details of how to report adverse events are available at the bottom of the page. Please refer to the respective SmPC for all licensed indications.
TAFINLAR + MEKINIST is the first and only targeted treatment available for patients with BRAF V600-positive advanced NSCLC1–3
Why choose TAFINLAR + MEKINIST?
In a retrospective analysis (N=36), treatment-naïve patients with BRAF V600E mutation had an overall response rate of 63.9% at Year 54
It has a well established safety profile1,2
It offers oral dosing1,2
BRAF V600E, mutation of the BRAF gene at valine (V) 600 to glutamate (E); NSCLC, non-small cell lung cancer; SmPC, summary of product characteristics.
References
Tafinlar (dabrafenib) Summary of Product Characteristics.
Mekinist (trametinib) Summary of Product Characteristics.
National Institute of Health and Care Excellence. Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer. Available at: https://www.nice.org.uk/guidance/ta898/chapter/1-Recommendations [Accessed June 2025].
Planchard D, et al. J Thorac Oncol 2022;17:103–115.
Planchard D, et al. Lancet Oncol 2017;18:1307–1316.
UK | June 2025 | FA-11217824
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.